|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2010-12-20
|
|
pubmed:abstractText |
To elucidate the role of ETS gene fusions in castration-resistant prostate cancer (CRPC), we characterized the transcriptome of 54 CRPC tumor samples from men with locally advanced or metastatic disease. Trefoil factor 3 (TFF3) emerged as the most highly differentially regulated gene with respect to ERG rearrangement status and resistance to hormone ablation therapy. Conventional chromatin immunoprecipitation (ChIP)-polymerase chain reaction and ChIP followed by DNA sequencing (ChIP-seq) revealed direct binding of ERG to ETS binding sites in the TFF3 promoter in ERG-rearranged prostate cancer cell lines. These results were confirmed in ERG-rearranged hormone-naive prostate cancer (HNPC) and CRPC tissue samples. Functional studies demonstrated that ERG has an inhibitory effect on TFF3 expression in hormone-naive cancer but not in the castration-resistant state. In addition, we provide evidence suggesting an effect of androgen receptor signaling on ERG-regulated TFF3 expression. Furthermore, TFF3 overexpression enhances ERG-mediated cell invasion in CRPC prostate cancer cells. Taken together, our findings reveal a novel mechanism for enhanced tumor cell aggressiveness resulting from ERG rearrangement in the castration-resistant setting through TFF3 gene expression.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1476-5586
|
|
pubmed:author |
pubmed-author:BanerjeeSampritS,
pubmed-author:BismarTarek ATA,
pubmed-author:ChenYing-BeiYB,
pubmed-author:ChinnaiyanArul MAM,
pubmed-author:DemichelisFrancescaF,
pubmed-author:LafargueChristopher JCJ,
pubmed-author:MertzKirsten DKD,
pubmed-author:PanYihangY,
pubmed-author:PernerSvenS,
pubmed-author:RickmanDavid SDS,
pubmed-author:RubinMark AMA,
pubmed-author:SetlurSunita RSR,
pubmed-author:SircarKanishkaK,
pubmed-author:VuongTerryT,
pubmed-author:YuJindanJ
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1031-40
|
|
pubmed:dateRevised |
2011-8-1
|
|
pubmed:meshHeading |
pubmed-meshheading:21170267-Chromatin Immunoprecipitation,
pubmed-meshheading:21170267-Disease Progression,
pubmed-meshheading:21170267-Gene Expression Profiling,
pubmed-meshheading:21170267-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:21170267-Humans,
pubmed-meshheading:21170267-Male,
pubmed-meshheading:21170267-Neoplasm Invasiveness,
pubmed-meshheading:21170267-Neoplasms, Hormone-Dependent,
pubmed-meshheading:21170267-Peptides,
pubmed-meshheading:21170267-Polymerase Chain Reaction,
pubmed-meshheading:21170267-Prostatic Neoplasms,
pubmed-meshheading:21170267-Receptors, Androgen,
pubmed-meshheading:21170267-Sequence Analysis, DNA,
pubmed-meshheading:21170267-Signal Transduction,
pubmed-meshheading:21170267-Trans-Activators,
pubmed-meshheading:21170267-Transcription Factors
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression.
|
|
pubmed:affiliation |
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10065, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
